Related Experiment Video

Updated: Jun 5, 2026

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

Pharmacokinetics of anti-tuberculosis drugs in children

Geetha Ramachandran1, A K Hemanth Kumar, Soumya Swaminathan

  • 1Tuberculosis Research Centre (Indian Council of Medical Research), Chennai, India.

Indian Journal of Pediatrics
|December 18, 2010
PubMed

Insights

Pediatric tuberculosis drug dosages may be inadequate. This review synthesizes pharmacokinetic data to guide optimal dosing, highlighting the need for more research linking drug levels to treatment outcomes in children.

Area of Science:

  • Pharmacology
  • Pediatrics
  • Infectious Diseases

Background:

  • Tuberculosis (TB) remains a leading cause of childhood mortality globally.
  • Current first-line anti-TB drug dosages may be insufficient for pediatric populations, especially younger children.

Purpose of the Study:

  • To review and synthesize existing pharmacokinetic data for anti-TB drugs in children.
  • To inform evidence-based recommendations for optimal pediatric TB drug dosing.

Main Methods:

  • A comprehensive literature search of the PubMed database (1970-present) was conducted.
  • Keywords included specific anti-TB drugs (rifampicin, isoniazid, pyrazinamide, ethambutol), pharmacokinetics, HIV, TB, nutrition, and children.
  • References from identified articles and recent meeting abstracts were also reviewed.

Main Results:

  • Pharmacokinetic data indicate that factors like age, nutritional status, HIV infection, and genetic variations can significantly affect anti-TB drug metabolism in children.
  • A critical gap exists, as most studies have not correlated drug concentrations with treatment success in pediatric TB.

Conclusions:

  • Further research is essential to establish the relationship between drug pharmacokinetics and treatment response in children with TB.
  • Specific studies investigating the impact of nutritional status and HIV on anti-TB drug pharmacokinetics in children are required.

More Related Videos

An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions12:17

An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions

Published on: May 8, 2017

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...